# ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

> **NCT04857645** · PHASE2 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 57 (actual)

## Conditions studied

- MDS
- AML

## Interventions

- **DRUG:** ASTX727
- **OTHER:** Donor Lymphocyte Infusions

## Key facts

- **NCT ID:** NCT04857645
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-22
- **Primary completion:** 2024-04-30
- **Final completion:** 2025-04-22
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857645, "ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04857645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*